This website is for informational purposes only and does not constitute medical advice. Read disclaimer
Thymosin Alpha-1
A naturally occurring thymic peptide that is one of the most clinically validated immune-modulating peptides, approved in multiple countries for hepatitis B/C and as an immune system adjuvant.
Overview
Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide originally isolated from thymosin fraction 5, a preparation of bovine thymus extract characterized by Allan Goldstein at George Washington University in the 1970s. It was the first thymic peptide to be sequenced, synthesized, and developed as a pharmaceutical product. Thymosin Alpha-1 plays a fundamental role in T-cell maturation and immune system regulation, acting as an endogenous immune modulator.
The clinical development of Thymosin Alpha-1 has been more extensive than most research peptides. It has been approved as a pharmaceutical product (under the brand name Zadaxin) in over 35 countries for the treatment of hepatitis B, hepatitis C (as an adjunct to interferon), and as a vaccine adjuvant. It has also been used clinically for various immunodeficiency states and as an immune booster in cancer patients. While it has not received FDA approval, it holds orphan drug status in the US for hepatitis B.
The mechanism of Thymosin Alpha-1 involves modulation of multiple arms of the immune system. It promotes T-cell maturation and differentiation, enhances natural killer cell activity, increases production of cytokines including IL-2 and interferon-gamma, and promotes dendritic cell function. Importantly, it acts as an immune modulator rather than a simple immune stimulant, meaning it can help normalize immune responses that are either deficient or overactive, depending on the context.
During the COVID-19 pandemic, Thymosin Alpha-1 received renewed attention. It was used in clinical protocols in several countries, particularly China, for patients with severe COVID-19. Retrospective studies suggested that Thymosin Alpha-1 treatment was associated with reduced mortality in critically ill COVID-19 patients, though prospective randomized trials are needed to confirm these observations. The peptide's ability to restore T-cell function and modulate the inflammatory response made it a rational candidate for addressing the immune dysregulation seen in severe COVID-19.